|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
|
31658955 |
2020 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
|
31605540 |
2020 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Positive concordance of KRAS alterations between ctDNA and tissue was negatively affected by a longer time period between blood and tissue sampling and was higher in colorectal cancer than in other malignancies.
|
31199507 |
2020 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies.
|
31636382 |
2020 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We first performed siRNA screen of KRAS growth dependency of a small panel of human cancer lines, and identified a subset of KRAS mutant cancer cells that were highly dependent on KRAS signaling.
|
31316177 |
2020 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The three RAS genes (HRAS, NRAS, and KRAS) comprise the most frequently mutated oncogene family in human cancer.
|
31815779 |
2020 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours<sup>1,2</sup>.
|
31666701 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We developed an approach to statistically humanize the mouse networks with data from human cancer and identified genes within the humanized CRC and PDAC networks synthetically lethal with mutant KRAS.
|
31521603 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
KRAS mutations and TP53 mutations were only presented in borderline or malignant tumors.
|
31077238 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The proto-oncogene KRAS belongs among the most frequently mutated genes in all types of cancer and is also very important oncogene related to colorectal tumors.
|
30661213 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
791 cancer-specific mutations were detected in plasma of 88% patients with KRAS hotspots detected in 70% of all patients.
|
30857943 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Moreover, we use the LITer gene circuit architecture to control gene expression of the cancer oncogene KRAS(G12V) and study its downstream effects through phospho-ERK levels and cellular proliferation.
|
31269201 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Here, we sought to examine KRAS activation in epithelial-to-mesenchymal transition (EMT) and generation of cancer stem-like cells (CSC).
|
31217166 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) is a dominantly (~95%) KRAS-mutant cancer that has extremely poor prognosis, in part this is due to its strong intrinsic resistance towards almost all therapeutic agents.
|
30653981 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Regulating cellular redox, targeting KRAS/AMPK signaling, or reversing metabolic reprogramming might be effective approaches to eliminate cancer stem cells (CSCs) and enhance chemosensitivity to GEM to improve the prognosis of PanCa patients.
|
31508487 |
2019 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We found that reduced miR-873 expression is associated with shorter patient survival in both cancers. miR-873 expression is significantly repressed in PDAC and TNBC cell lines and inversely correlated with KRAS levels.
|
30654191 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
While rates of detectable somatic cancer-driver events between IE and DE are not statistically significant (P > 0.05), KRAS activating mutations were more prevalent in DE.
|
30428062 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Patients with RAS-altered versus wild-type RAS malignancies had significantly worse overall survival (OS) (P=0.02 [multivariate]), with KRAS alterations in particular showing shorter survival.
|
31782524 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The three canonical genes (HRAS, NRAS, and KRAS) are archetypes of the superfamily of small GTPases and are the most common oncogenes in human cancer.
|
31386964 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the probability of codon 12 mutation in K-ras gene is increased in patients with cardia cancer, and fascin is highly expressed in mutant patients, which is positively correlated with the mutations in K-ras gene.
|
30675241 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In this review we aim to describe the prevalence and importance of KRAS mutation in cancer and associated problems for the clinical handling of patients harboring these tumors.
|
29432815 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In contrast, mutant larvae developed enlarged livers when induced with liver specific expression of Kras<sup>G12V</sup>, one of the common mutations of KRAS that leads to cancer in humans.
|
31208154 |
2019 |
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
TEAD deregulation affects well-established cancer genes such as KRAS, BRAF, LKB1, NF2, and MYC, and its transcriptional output plays an important role in tumor progression, metastasis, cancer metabolism, immunity, and drug resistance.
|
31212916 |
2019 |
|
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
KRAS mutations do not appear to be associated with a high risk of malignancy in PBM, while IL-33 overexpression may provide a pro-oncogenic microenvironment in the gallbladder mucosa of patients with PBM.
|
30882917 |
2019 |
|
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In normal cells, KRAS-activity is tightly controlled, but with specific mutations, the KRAS protein is persistently activated, giving cells a growth advantage resulting in cancer.
|
31399087 |
2019 |